Rezultaty - Andrew McDonald
- Rezultaty 1 - 20 Rezultaty od 25
- Idź do następnej strony
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
EFFICACY AND SAFETY OF NEMTABRUTINIB VERSUS CHEMOIMMUNOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITHOUT TUMOR PROTEIN 5... od Guilherme Fleury Perini, Marek Hus, Shang‐Ju Wu, Péter Ilonczai, Chen Chen, Jing Yang, Mahfooz Farooqui, Andrew McDonald
Wydane 2023Artigo -
13
Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgki... od Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, José Salvador Rodrigues de Oliveira, Valéria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhi̇t Özcan, Naohiro Sekiguchi, Monika Raut, Hilde Giezek, Akash Nahar, John Kuruvilla
Wydane 2020Artigo -
14
Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in Fir... od Mohamed A. Kharfan‐Dabaja, Myriam Labopin, Ernesto Ayala, Ali Bazarbachi, Didier Blaise, Yener Koç, Jan Vydra, Alessandro Busca, Luca Castagna, Yana Novis, Andrew McDonald, Claude‐Eric Bulabois, Christoph Schmid, Concha Herrera, Édouard Forcade, Fabio Ciceri, Jaime Sanz, Arnon Nagler, Mohamad Mohty
Wydane 2021Artigo -
15
886MO Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refrac... od Pier Luigi Zinzani, Rod Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, José Salvador Rodrigues de Oliveira, Valéria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhi̇t Özcan, Naohiro Sekiguchi, Monika Raut, Ying Zhu, Akash Nahar, Patricia Marinello, John Kuruvilla
Wydane 2020Artigo -
16
HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN od Pier Luigi Zinzani, Monika Raut, Todd L. Saretsky, Rod Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, José Salvador Rodrigues de Oliveira, Valéria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhi̇t Özcan, Naohiro Sekiguchi, Hilde Giezek, Akash Nahar, John Kuruvilla
Wydane 2021Artigo -
17
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma od Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, José Salvador Rodrigues de Oliveira, Valéria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhi̇t Özcan, Naohiro Sekiguchi, Ying Zhu, Monika Raut, Todd L. Saretsky, Akash Nahar, John Kuruvilla
Wydane 2021Artigo -
18
Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma od Andrew McDonald, Estelle Verburgh, Manuel Gotti, Antonio Pinto, Jan Maciej Zaucha, Vladimir Ivanov, В Я Мельниченко, Heidi Móciková, Muhi̇t Özcan, Caterina Patti, João Farias, Iara Gonçalves, Olha Kuchkova, Jiřı́ Mayer, Güray Saydam, Sarah Tomassetti, Kumudu Pathiraja, Katherine Elizabeth Ryland, Patricia Marinello, Wojciech Jurczak
Wydane 2023Artigo -
19
Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL) od Andrew McDonald, Estelle Verburgh, Manuel Gotti, Antonio Pinto, Jan Maciej Zaucha, Vladimir Ivanov, В Я Мельниченко, Heidi Móciková, Muhi̇t Özcan, Caterina Patti, João Samuel de Holanda Farias, Inês Gonçalves, Olha Kuchkova, Jiřı́ Mayer, Güray Saydam, Sarah Tomassetti, Kumudu Pathiraja, Kristen Ryland, Samhita Chakraborty, Wojciech Jurczak
Wydane 2023Artigo -
20
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial od Andrew H. Wei, Pau Montesinos, Vladimir Ivanov, Courtney D. DiNardo, Jan Novák, Kamel Laribi, Inho Kim, Don A. Stevens, Walter Fiedler, Maria Pagoni, Olga Samoilova, Yu Hu, Αchilles Anagnostopoulos, Julie Bergeron, Jing‐Zhou Hou, Vidhya Murthy, Takahiro Yamauchi, Andrew McDonald, Brenda Chyla, Sathej Gopalakrishnan, Qi Jiang, Wellington Mendes, John Hayslip, Panayiotis Panayiotidis
Wydane 2020Artigo
Narzędzie wyszukiwania:
Podobne hasła
Medicine
Internal medicine
Oncology
Cancer
Lymphoma
Biology
Immunotherapy
Pembrolizumab
Immunology
Nursing
Surgery
Brentuximab vedotin
Chemotherapy
Environmental health
Gastroenterology
Genetics
Hodgkin lymphoma
Population
Quality of life (healthcare)
Astrobiology
Cell biology
Confidence interval
Cyclophosphamide
Gene
Graft-versus-host disease
Hazard ratio
Leukemia
Myeloid leukemia
Neuroscience
Refractory (planetary science)